User menu

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.

Bibliographic reference Godelaine, Danièle ; Carrasco Bertrand, Javier ; Brasseur, Francis ; Neyns, Bart ; Thielemans, Kris ; et. al. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.. In: Cancer immunology, immunotherapy : CII, Vol. 56, no. 6, p. 753-9 (2007)
Permanent URL
  1. Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815 II T lymphocyte-mediated cytolysis. J Exp Med 152:1184–1193
  2. Boon T, Coulie PG, Van den Eynde B, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:6.1–6.34
  3. Brasseur F (1999) Melanoma: Brussels Melanoma cell lines. In: Masters JRW, Palsson B (eds) Human cell culture, vol 1. Kluwer, Dordrecht, pp 275–282
  4. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S (2001) An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61:5544–5551
  5. Espevik T, Nissen-Meyer J (1986) A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99–105
  6. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921–930
  7. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethé B, De Plaen E, Velu T, Coulie PG (2005) High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201:241–248
  8. Godelaine D., Carrasco J., Lucas S., Karanikas V., Schuler-Thurner B., Coulie P. G., Schuler G., Boon T., Van Pel A., Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide, 10.4049/jimmunol.171.9.4893
  9. HAAS GILBERT G., D'CRUZ OSMOND J., DE BAULT LAWRENCE E., Distribution of Human Leukocyte Antigen-ABC and -D/DR Antigens in the Unfixed Human Testis, 10.1111/j.1600-0897.1988.tb00234.x
  10. Herman J, Jongeneel V, Kuznetsov D, Coulie PG (1999) Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid. Tissue Antigens 53:111–121
  11. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T (1991) Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T (eds) XIth international histocompatibility workshop and conference, vol 1. Oxford University Press, New York, p 1065
  12. Jäger E, Chen Y-T, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270
  13. Lee TD (1990) Distributions of HLA antigens. In: Lee J (ed) The HLA system A new approach. Springer, Berlin Heidelberg New York, pp 141–178
  14. Lucas S, De Plaen E, Boon T (2000) MAGE-B5, MAGE-B6, MAGE-C2 and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int J Cancer 87:55–60
  15. Lurquin C, Lethé B, Corbière V, Théate I, van Baren N, Coulie PG, Boon T (2005) Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201:249–257
  16. Ma W, Germeau C, Vigneron N, Maernoudt A-S, Morel S, Boon T, Coulie PG, Van den Eynde B (2004) Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int J Cancer 109:698–702
  17. Rimoldi D., Rubio-Godoy V., Dutoit V., Lienard D., Salvi S., Guillaume P., Speiser D., Stockert E., Spagnoli G., Servis C., Cerottini J.-C., Lejeune F., Romero P., Valmori D., Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma, 10.4049/jimmunol.165.12.7253
  18. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915
  19. Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P (2000) A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 60:6272–6275
  20. Traversari C, van der Bruggen P, Van den Eynde B, Hainaut P, Lemoine C, Ohta N, Old L, Boon T (1992) Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35:145–152
  21. Tynan FE, Elhassen D, Purcell AW, Burrows JM, Borg NA, Miles JJ, Williamson NA, Green KJ, Tellam J, Kjer-Nielsen L, McCluskey J, Rossjohn J, Burrows SR (2005) The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J Exp Med 202:1249–1260
  22. Van den Eynde B, van der Bruggen P. Peptide database of T-cell defined tumor antigens. URL:
  23. van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51–64